mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation.
Curr Allergy Asthma Rep
; 23(3): 195-200, 2023 03.
Article
in English
| MEDLINE | ID: covidwho-2209517
ABSTRACT
PURPOSE OF REVIEW The COVID-19 vaccines have proved essential in our defense against the COVID-19 pandemic. However, concerns regarding allergic reactions to the vaccines persist to this day. Herein, we review the data regarding the frequency of allergic reactions to the COVID-19 vaccines, the epidemiology, and the management of patients reporting vaccine allergic reactions. RECENT FINDINGS:
Although initial reports emphasized a high risk of anaphylaxis to the COVID-19 vaccines, more recent data demonstrate similar rates of anaphylaxis to the COVID-19 vaccines as to other vaccines. Alternative explanations for increased rates of apparent allergic reactions are discussed, including the role for stress-related and nocebo responses. COVID-19 vaccines and mRNA vaccine technology are overwhelmingly safe and well-tolerated by most patients. Careful history and case review will enable the discerning physician to safely vaccinate most patients. Rare patients with objective signs and symptoms of anaphylaxis may be candidates for alternatives to vaccination including monoclonal antibodies.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Anaphylaxis
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Allergy Asthma Rep
Journal subject:
Allergy and Immunology
Year:
2023
Document Type:
Article
Affiliation country:
S11882-023-01065-2
Similar
MEDLINE
...
LILACS
LIS